论文部分内容阅读
目的探讨COPD患者BALF中IL-8水平及布地奈德对其调节作用。方法选择本科2009年7月-2013年7月COPD急性发作期患者按就诊时间分为常规组和治疗组各60例。常规组予综合治疗,治疗组在此基础上进行布地奈德雾化吸入治疗,疗程均为3周,对2组治疗前、治疗1周、治疗3周BALF中IL-8水平进行检测,并与GOLD分级进行相关性分析。结果治疗前、治疗1周、治疗3周IL-8浓度常规组分别为(9.68±1.46)pg/ml、(9.45±1.63)pg/ml、(8.70±2.00)pg/ml,治疗组分别为(9.35±1.49)pg/ml、(8.75±1.57)pg/ml、(6.27±1.96)pg/ml,治疗前2组差异无统计学意义(P>0.05);治疗1周后2组差异有统计学意义(P<0.05),治疗3周后2组差异有统计学意义(P<0.01);BALF中IL-8水平与GOLD分级呈正相关(r=0.519,P<0.01)。结论 COPD患者BALF中IL-8能反映COPD气道炎症情况,布地奈德能显著降低BALF中IL-8水平。
Objective To investigate the level of IL-8 in BALF of COPD patients and the effect of budesonide on it. Methods From July 2009 to July 2013, patients undergoing acute exacerbation of COPD were divided into two groups according to their duration of treatment: 60 cases in each group. The patients in the conventional group were treated with inhalation of budesonide for 3 weeks. The levels of IL-8 in BALF before treatment, 1 week and 3 weeks after treatment were measured in the treatment group Correlation analysis with GOLD classification. Results Before treatment, the levels of IL-8 in the treatment group were (9.68 ± 1.46) pg / ml, (9.45 ± 1.63) pg / ml and (8.70 ± 2.00) pg / (9.35 ± 1.49) pg / ml, (8.75 ± 1.57) pg / ml and (6.27 ± 1.96) pg / ml, respectively. There was no significant difference between the two groups before treatment (P> 0.05) (P <0.05). There was significant difference between the two groups after 3 weeks of treatment (P <0.01). The level of IL-8 in BALF was positively correlated with the grade of GOLD (r = 0.519, P <0.01). Conclusions IL-8 in BALF of COPD patients can reflect airway inflammation of COPD, and budesonide can significantly reduce the level of IL-8 in BALF.